Meeting
2021 Gastrointestinal Cancers Symposium
Exposure-response (E-R) efficacy and safety (E-S) analyses of tremelimumab as monotherapy or in combination with durvalumab in patients (pts) with unresectable hepatocellular carcinoma (uHCC).
Authors
Xuyang Song
AstraZeneca, Gaithersburg, MD
Xuyang Song , Robin Kate Kelley , Anis Khan , Nathan Standifer , Rajesh Krishna , Lucy Liu , Kun Wang , Michelle Green , Patricia McCoon , Alejandra Negro , Philip He , Rajesh Narwal , Ghassan K. Abou-Alfa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Hepatobiliary Cancer
Track
Hepatobiliary Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02519348
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr 313)
DOI
10.1200/JCO.2021.39.3_suppl.313
Abstract #
313
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
T-cell receptor pharmacodynamics associated with survival and response to tremelimumab (T) in combination with durvalumab (D) in patients (pts) with unresectable hepatocellular carcinoma (uHCC).
First Author: Patricia McCoon
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Presence and impact of antidrug antibodies (ADAs) to tremelimumab (T) or durvalumab (D) in the phase 3 HIMALAYA study of unresectable hepatocellular carcinoma (uHCC).
First Author: Oxana V. Crysler
Poster
2024 ASCO Annual Meeting
Phase 2/3 study of livmoniplimab in combination with budigalimab in patients with locally advanced or metastatic hepatocellular carcinoma.
First Author: Ghassan K. Abou-Alfa
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Safety and efficacy of durvalumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from the phase 2 study 22 (NCT02519348).
First Author: Ho Yeong Lim